Phaseline

Targets › TPO

TPO (Thyroid peroxidase): drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 4; Metabolic and endocrine; next expected readout Jul 2030.

Iodination and coupling of the hormonogenic tyrosines in thyroglobulin to yield the thyroid hormones T(3) and T(4). (UniProt, P07202)

Open in Phaseline: the race on TPO, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
The First Affiliated Hospital with Nanjing Medical UniversityMethimazole
Thyroid peroxidase inhibitor
TPOPhase 4Graves DiseaseJul 2030

Conditions

Graves Disease (1)

Modalities

small molecule (1)

Companies

The First Affiliated Hospital with Nanjing Medical University (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.